Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market - 2026-2032
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market reached US$ $8.12 billion in 2025 and is expected to reach US$ 40.95 billion by 2035, growing with a CAGR of 17.55% during the forecast period 2026-2035.
The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Stage
Both primary and secondary data sources have been used in the global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Stage
- Stage F0*
- Prevalence Population
- Incidence Population
- Diagnosed Population
- Treatment Population
- Stage F1
- Stage F2
- Stage F3
- Stage F4 ‘*’ Indicates similar breakdown for each stage
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. DISEASE OVERVIEW
1.1. Introduction
1.2. Causes
1.3. Pathophysiology
1.4. Patient-related risk factors
1.5. Signs and Symptoms
1.6. Diagnosis
1.7. Treatment
2. EXECUTIVE SUMMARY
2.1. Overview
2.2. Epidemiology and Forecast
2.3. Factors influencing epidemiology
3. EPIDEMIOLOGY BY STAGE
3.1. Stage F0*
3.1.1. Overview
3.1.2. Prevalence Population
3.1.3. Incidence Population
3.1.4. Diagnosed Population
3.1.5. Treatment Population
3.2. Stage F1
3.3. Stage F2
3.4. Stage F3
3.5. Stage F4 ‘*’ Indicates similar breakdown for each stage
4. EPIDEMIOLOGY BY REGION
4.1. North America
4.1.1. Epidemiology
4.1.1.1. Prevalence Population
4.1.1.2. Incidence Population
4.1.1.3. Diagnosed Population
4.1.1.4. Treatment Population
4.1.2. U.S
4.1.3. Canada
4.2. Europe
4.2.1. Epidemiology
4.2.1.1. Prevalence Population
4.2.1.2. Incidence Population
4.2.1.3. Diagnosed Population
4.2.1.4. Treatment Population
4.2.2. Germany
4.2.3. UK
4.2.4. France
4.2.5. Italy
4.2.6. Spain
4.2.7. Rest of Europe
4.3. Asia Pacific
4.3.1. Epidemiology
4.3.1.1. Prevalence Population
4.3.1.2. Incidence Population
4.3.1.3. Diagnosed Population
4.3.1.4. Treatment Population
4.3.2. China
4.3.3. India
4.3.4. Japan
4.3.5. South Korea
4.3.6. Rest of Asia Pacific
4.4. Latin America
4.4.1. Epidemiology
4.4.1.1. Prevalence Population
4.4.1.2. Incidence Population
4.4.1.3. Diagnosed Population
4.4.1.4. Treatment Population
4.4.2. Mexico
4.4.3. Brazil
4.4.4. Argentina
4.4.5. Rest of Latin America
4.5. Middle East and Africa
4.5.1. Epidemiology
4.5.1.1. Prevalence Population
4.5.1.2. Incidence Population
4.5.1.3. Diagnosed Population
4.5.1.4. Treatment Population
4.6. Asia-Pacific
4.6.1. Introduction
4.6.2. Key Region-Specific Dynamics
4.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
4.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
4.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
4.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
4.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
4.6.7.1. China
4.6.7.2. India
4.6.7.3. Japan
4.6.7.4. South Korea
4.6.7.5. Rest of Asia-Pacific
4.7. Middle East and Africa
4.7.1. Introduction
4.7.2. Key Region-Specific Dynamics
4.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
4.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
4.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
4.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
5. COMPETITIVE LANDSCAPE
5.1. Competitive Scenario
5.2. Market Positioning/Share Analysis
5.3. Mergers and Acquisitions Analysis
6. COMPANY PROFILES
6.1. Madrigal Pharmaceuticals*
6.1.1. Company Overview
6.1.1.1. Product Portfolio
6.1.1.2. Product Description
6.1.1.3. Product Key Performance Indicators (KPIs)
6.1.1.4. Historic and Forecasted Product Sales
6.1.1.5. Product Sales Volume
6.1.2. Financial Overview
6.1.2.1. Company Revenue’s
6.1.2.2. Geographical Revenue Shares
6.1.2.3. Revenue Forecasts
6.1.3. Key Developments
6.1.3.1. Mergers & Acquisitions
6.1.3.2. Key Product Development Activities
6.1.3.3. Regulatory Approvals etc.
6.1.3.4. SWOT Analysis
6.2. Novo Nordisk A/S
6.3. Boehringer Ingelheim International GmbH.
6.4. 89bio, Inc.
6.5. Inventiva.
6.6. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
6.7. Sagimet Biosciences.
6.8. Akero Therapeutics, Inc. * Similar data will be provided for each market player. LIST NOT EXHAUSTIVE
7. APPENDIX
7.1. About Us and Services
7.2. Contact Us
1.1. Introduction
1.2. Causes
1.3. Pathophysiology
1.4. Patient-related risk factors
1.5. Signs and Symptoms
1.6. Diagnosis
1.7. Treatment
2. EXECUTIVE SUMMARY
2.1. Overview
2.2. Epidemiology and Forecast
2.3. Factors influencing epidemiology
3. EPIDEMIOLOGY BY STAGE
3.1. Stage F0*
3.1.1. Overview
3.1.2. Prevalence Population
3.1.3. Incidence Population
3.1.4. Diagnosed Population
3.1.5. Treatment Population
3.2. Stage F1
3.3. Stage F2
3.4. Stage F3
3.5. Stage F4 ‘*’ Indicates similar breakdown for each stage
4. EPIDEMIOLOGY BY REGION
4.1. North America
4.1.1. Epidemiology
4.1.1.1. Prevalence Population
4.1.1.2. Incidence Population
4.1.1.3. Diagnosed Population
4.1.1.4. Treatment Population
4.1.2. U.S
4.1.3. Canada
4.2. Europe
4.2.1. Epidemiology
4.2.1.1. Prevalence Population
4.2.1.2. Incidence Population
4.2.1.3. Diagnosed Population
4.2.1.4. Treatment Population
4.2.2. Germany
4.2.3. UK
4.2.4. France
4.2.5. Italy
4.2.6. Spain
4.2.7. Rest of Europe
4.3. Asia Pacific
4.3.1. Epidemiology
4.3.1.1. Prevalence Population
4.3.1.2. Incidence Population
4.3.1.3. Diagnosed Population
4.3.1.4. Treatment Population
4.3.2. China
4.3.3. India
4.3.4. Japan
4.3.5. South Korea
4.3.6. Rest of Asia Pacific
4.4. Latin America
4.4.1. Epidemiology
4.4.1.1. Prevalence Population
4.4.1.2. Incidence Population
4.4.1.3. Diagnosed Population
4.4.1.4. Treatment Population
4.4.2. Mexico
4.4.3. Brazil
4.4.4. Argentina
4.4.5. Rest of Latin America
4.5. Middle East and Africa
4.5.1. Epidemiology
4.5.1.1. Prevalence Population
4.5.1.2. Incidence Population
4.5.1.3. Diagnosed Population
4.5.1.4. Treatment Population
4.6. Asia-Pacific
4.6.1. Introduction
4.6.2. Key Region-Specific Dynamics
4.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
4.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
4.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
4.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
4.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
4.6.7.1. China
4.6.7.2. India
4.6.7.3. Japan
4.6.7.4. South Korea
4.6.7.5. Rest of Asia-Pacific
4.7. Middle East and Africa
4.7.1. Introduction
4.7.2. Key Region-Specific Dynamics
4.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
4.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
4.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group
4.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
5. COMPETITIVE LANDSCAPE
5.1. Competitive Scenario
5.2. Market Positioning/Share Analysis
5.3. Mergers and Acquisitions Analysis
6. COMPANY PROFILES
6.1. Madrigal Pharmaceuticals*
6.1.1. Company Overview
6.1.1.1. Product Portfolio
6.1.1.2. Product Description
6.1.1.3. Product Key Performance Indicators (KPIs)
6.1.1.4. Historic and Forecasted Product Sales
6.1.1.5. Product Sales Volume
6.1.2. Financial Overview
6.1.2.1. Company Revenue’s
6.1.2.2. Geographical Revenue Shares
6.1.2.3. Revenue Forecasts
6.1.3. Key Developments
6.1.3.1. Mergers & Acquisitions
6.1.3.2. Key Product Development Activities
6.1.3.3. Regulatory Approvals etc.
6.1.3.4. SWOT Analysis
6.2. Novo Nordisk A/S
6.3. Boehringer Ingelheim International GmbH.
6.4. 89bio, Inc.
6.5. Inventiva.
6.6. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
6.7. Sagimet Biosciences.
6.8. Akero Therapeutics, Inc. * Similar data will be provided for each market player. LIST NOT EXHAUSTIVE
7. APPENDIX
7.1. About Us and Services
7.2. Contact Us
